vTv Therapeutics (NASDAQ:VTVT) Lowered to “Hold” Rating by Zacks Research

Zacks Research cut shares of vTv Therapeutics (NASDAQ:VTVT) from a strong-buy rating to a hold rating in a research note released on Thursday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. BTIG Research reissued a “buy” rating and set a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday, March 11th. Evercore assumed coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target for the company. Finally, Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Stock Up 3.7%

Shares of VTVT stock opened at $32.76 on Thursday. vTv Therapeutics has a 12-month low of $14.00 and a 12-month high of $44.00. The company has a market capitalization of $129.07 million, a P/E ratio of -35.23 and a beta of 0.27. The firm has a 50-day moving average price of $34.70 and a 200 day moving average price of $35.04.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $1.44. The firm had revenue of $36.84 million for the quarter, compared to the consensus estimate of $20.00 million. As a group, research analysts expect that vTv Therapeutics will post -2.19 earnings per share for the current year.

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. acquired a new stake in vTv Therapeutics in the 4th quarter valued at about $221,000. 683 Capital Management LLC acquired a new stake in vTv Therapeutics in the 4th quarter valued at about $731,000. Geode Capital Management LLC grew its position in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP raised its stake in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after buying an additional 51,000 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.